References:
- Kalbus O.I. (2019a) ImunologIchnI markeri rozvitku mIastenIYi. Ukr. med. chasopis, 2(2)(130): 24—26.
- Kalbus O.I. (2019b) Mediko-statistichnI ta epIdemIologIchnI harakteristiki poshirenostI mIastenIYi v UkraYinI. Ukr. med. chasopis, 4(2)(132): 42—45.
- Akcam T., Ozdil A., Kavurmaci O. et al. (2017) The effect of preoperative AchR-AB level to the prognosis in operated myasthenia gravis patients. Open J. Thorac. Surg., 07(04): 62–69.
- Andersen J.B., Heldal A.T., Engeland A., Gilhus N.E. (2014) Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries. Acta Neurol. Scandinav., 198: 26–31.
- Aurangzeb S., Tariq M., Irshad M. et al. (2009) Relationship between anti-acetylcholine receptor antibody titres and severity of myasthenia gravis. J. Pak. Med. Assoc., 59(5): 289–292.
- Barohn R., Mcintire D., Herbelin L. et al. (1998) Reliability testing of the Quantitative Myasthenia Gravis Scorea. Ann. New York Acad. Sci., 841(1): 769–772.
- Bartoccioni E., Scuderi F., Minicuci G. et al. (2006) Anti-MuSK antibodies: Correlation with myasthenia gravis severity. Neurology, 67(3): 505–507.
- Blum S., Lee D., Gillis D. et al. (2015) Clinical features and impact of myasthenia gravis disease in Australian patients. J. Clin. Neurosci., 22(7): 1164–1169.
- Breiner A., Widdifield J., Katzberg H.D. et al. (2016) Epidemiology of myasthenia gravis in Ontario, Canada. Neuromusc. Dis., 26(1): 41–46.
- Burns T., Sadjadi R., Utsugisawa K. et al. (2016) International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle Nerve, 54(6): 1015–1022.
- Carr A.S., Cardwell C.R., McCarron P.O., McConville J. (2010) A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol., 10: 46.
- Engel A.G. (Ed.) (2012) Myasthenia gravis and myasthenic disorders (2 ed). Oxford University Press, Oxford, 304 p.
- Jaretzki A., Barohn R.J., Ernstoff R.M. et al. (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55: 16–23.
- Kulaksizoglu I. (2007) Mood and anxiety disorders in patients with myasthenia gravis: aetiology, diagnosis and treatment. CNS Drugs, 21: 473–481.
- Nagappa M., Mahadevan A., Gangadhar Y. et al. (2019) Autoantibodies in acquired myasthenia gravis: сlinical phenotype and immunological correlation. Acta Neurol. Scandinav., 139(5): 428–437.
- Romi F., Skeie G., Aarli J., Gilhus N. (2000) The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Arch. Neurol., 57(11): 1596–600.
- Šimundić A.M. (2009) Measures of diagnostic accuracy: basic definitions. EJIFCC, 19(4): 203–211.
- Vinge L., Jakobsen J., Andersen H. (2018) Muscle weakness and functional disability in patients with myasthenia gravis. Musc. Nerv., 59(2): 218–223.
- Wolfe G., Herbelin L., Nations S. et al. (1999) Myasthenia gravis activities of daily living profile. Neurology, 52(7): 1487–1487.